Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar 12;3(1):5.
doi: 10.1186/2191-1991-3-5.

Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey

Onur Baser  1 , Erdem Baser, Akif Altinbas, Abdulkadir Burkan
Affiliations

Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey

Onur Baser et al. Health Econ Rev. .

Abstract

Objective: This study aimed to apply the previously validated severity index for rheumatoid arthritis (SIFRA) to prevalent rheumatoid arthritis (RA) groups in Turkey and determine the effect of RA severity on health care costs and biologic use.

Methods: This retrospective study used the Turkish national health insurance database MEDULA (June 1, 2009-December 31, 2011). Prevalent RA patients were required to be age 18 to 99, have two RA diagnoses at least 60 days apart and be continuously enrolled 1 year prior to (baseline period) and post (follow-up period) index date, which was the first RA claim during the identification period (June 1, 2010-December 31, 2010). SIFRA was calculated for the baseline period. Total health care costs and biologic use were examined for the follow-up period. The chi-square test was used to determine the association between SIFRA score terciles and outcomes. Generalized linear models were applied to determine health care costs while multivariate logistic regression determined the effect of SIFRA on outcome measures for biologic use.

Results: A total of 1,920 patients were identified. The mean SIFRA score was 14.21, and 7.05 (49.57%) of the mean composed of clinical and functional status variables, followed by 6.32 (44.47%) for medications, 0.48 (3.40%) for radiology and laboratory findings, and 0.32 (2.25%) for extra-articular manifestation. There was a significant variation in scores across cities. After controlling for age, gender, region, and comorbidity index, patients in the high SIFRA tercile were 5.16 times more likely to be prescribed biologics (p<0.001, confidence interval [CI]: 3.46-7.69), and incurred annual health care costs that were €2,091 higher (p<0.001, CI: €1,557 - €2,625) than those in the low SIFRA score tercile.

Conclusion: RA severity varies throughout Turkey and is a significant determinant of health care costs and biologic therapy use. Therefore, future comparative effectiveness studies should include the severity measure in their analysis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study period.
Figure 2
Figure 2
Rheumatoid arthritis severity distribution (by SIFRA terciles) across cities in Turkey.
Figure 3
Figure 3
SIFRA scores and health care costs.
Figure 4
Figure 4
Association between SIFRA Scores and biologic use.
See this image and copyright information in PMC

References

    1. Markenson JA. Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis. Semin Arthritis Rheum. 1991;3(2 Suppl 1):4–12. - PubMed
    1. Lundkvist J, Kastäng F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ. 2008;3(Suppl 2):s49–s60. - PubMed
    1. Alarcón GS. Epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 1995;3(3):589–604. - PubMed
    1. Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum. 2003;3(4):917–926. doi: 10.1002/art.10897. - DOI - PubMed
    1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis Rheum. 2008;3(1):15–25. doi: 10.1002/art.23177. - DOI - PubMed

LinkOut - more resources